

OUTSOURCED PHARMACEUTICAL SERVICES SECTOR CASE STUDY Thermo Fisher Scientific Announced Acquisition of Pharmaceutical Product Development (PPD)

M&A Advisory | Growth Capital | Recapitalizations | Board Advisory | Strategic Evaluations




April 2021

www.delanceystreetpartners.com

300 Barr Harbor Drive | Suite 420 | West Conshohocken | PA | 19428



- Announced: April 15, 2021
- Status: Pending
- Acquiror: Thermo Fisher Scientific ("Thermo Fisher")
- Enterprise Value: \$17.4 billion
 - All cash transaction whereby PPD shareholders will receive \$47.50 per share, and Thermo Fisher will assume approximately \$3.5 billion of net debt
 - 23.8% premium (1)
 - 19.9x FY 2020 Adjusted EBITDA of \$875.7 million ⁽²⁾
 - Thermo Fisher has obtained committed bridge financing for a portion of the purchase price (up to 3x 2020 Adjusted EBITDA), and the remainder of purchase price will be paid with cash on hand
- Prior to the announcement, holders of approximately 60% of PPD's shares delivered approval by written consent. No further action by other PPD shareholders is required to approve the transaction
- The transaction is expected to close by the end of 2021, subject to regulatory approvals
- Following closing, PPD will become part of Thermo Fisher's Laboratory Products and Services segment
- Thermo Fisher said it plans to have a number of executives of PPD join the company post-close, however no formal decisions have been made
- According to PE Hub, private equity firm Hellman & Friedman will produce a ~5.5x blended multiple on its original investment of \$1.7 billion in PPD, (nearly \$8 billion profit), and Caryle will receive more than a 3.0x return on its nearly \$2 billion investment



Overview of PPD

- PPD is a global contract research organization (CRO) that provides clinical trial and laboratory services to pharmaceutical, biotechnology, medical device, and government organizations
- The company is headquartered in Wilmington, North Carolina and employs approximately 26,000 people across 93 offices in 46 countries
- PPD was founded in 1985 by entrepreneur and philanthropist Fred Eshelman who took the firm public in 1996
- During the past five years, PPD has supported over 400 drug approvals globally, conducted clinical trials in over 100 countries, and contributed to all Phase III COVID-19 vaccine trials with funding from the U.S. government


(1) Premium over closing price on April 13, 2021, the last date before news of the deal was first reported.

DELANCEY STREET

Source: Company press releases, investor presentations, public filings, and PitchBook

⁽²⁾ Sourced from PPD 2020 Annual Report


PPD vs. Other DSP Outsourced Pharma Services Companies (Stock Price Performance) ^{(1) (2) (3)}



(1) Source: PitchBook

(2) DSP Outsourced Pharma Services Companies include: ICON, PRA Health, PPD, IQVIA, Charles River Laboratories, Medpace, Syneos, UDG Healthcare, and LabCorp

(3) PPD went public on the NYSE on February 5, 2020




COMPANY	STOCK PERFORMANCE AND COMPANY DATA					MARGINS		GROWTH		VALUATION DATA		
		30 Day	YTD	Market Value	Enterprise Value	Gross Profit	EBITDA LTM	Long-Term EPS	3-Year Revs	EV / Revs	EV / Ebitda	
Company	4/16/2021	% Change	% Change	(\$mm)	(\$mm)	% Margin	% Margin	% Growth	CAGR	LTM	LTM	2021
Outsourced Pharma Services												
Medpace	185.00	12.2%	32.9%	6,610.8	6,497.7	30.1%	21.8%	N.A.	27.8%	7.0x	32.2x	30.2x
Pharmaceutical Product Development	45.80	20.3%	33.8%	16,049.6	19,768.3	38.4%	16.0%	16.9%	15.3%	4.2x	26.3x	20.0x
IQVIA	214.13	12.9%	19.5%	41,063.1	52,344.1	34.0%	19.6%	16.2%	4.9%	4.6x	23.5x	18.6x
PRA Health Sciences	161.80	10.0%	29.0%	10,443.2	11,410.5	27.3%	15.5%	11.3%	11.6%	3.6x	23.1x	19.0x
Charles River Laboratories	320.37	9.5%	28.2%	16,085.8	18,045.5	36.7%	28.2%	14.0%	15.9%	6.2x	21.9x	21.4x
lcon	205.20	12.7%	5.2%	10,832.1	10,423.7	29.2%	19.1%	11.3%	16.6%	3.7x	19.5x	17.8x
Syneos Health	85.79	10.9%	25.9%	8,895.6	11,883.7	23.0%	14.3%	N.A.	18.2%	2.7x	18.8x	15.5x
UDG Healthcare	11.57	9.3%	8.9%	2,914.9	3,049.8	30.9%	17.0%	6.9%	2.1%	2.4x	14.0x	12.4x
Laboratory Corporation of America	259.41	8.6%	27.4%	25,329.0	30,785.3	35.4%	26.2%	10.8%	9.6%	2.2x	8.4x	9.3x
Group Mean		11.8%	23.4%	\$15,358.3	\$18,245.4	31.7%	19.8%	12.5%	13.6%	4.07x	20.9x	18.3x
Group Median		10.9%	27.4%	10,832.1	11,883.7	30.9%	19.1%	11.3%	15.3%	3.73x	21.9x	18.6x
Group Max		20.3%	33.8%	41,063.1	52,344.1	38.4%	28.2%	16.9%	27.8%	7.02x	32.2x	30.2x
Group Min		8.6%	5.2%	2,914.9	3,049.8	23.0%	14.3%	6.9%	2.1%	2.20x	8.4x	9.3x

EV / LTM EBITDA - CURRENT TRADING PERFORMANCE

Thermo Fisher Deal Rationale


- Thermo Fisher is best known in the industry for its laboratory instruments and tests, however in 2017 the company acquired Patheon in 2017 in an effort to increase its drug manufacturing capabilities and expand into the pharma & biotech sectors
- PPD further enhances Thermo Fisher's offering to its pharma and biotech clients, bringing a proven drug development platform, patient recruitment experience, and laboratory services capabilities
- The combined company's capabilities and knowledge in serving the pharma and biotech industry will enable new solutions for customers that create the potential to reduce the time and cost of the drug development process
- According to Thermo Fisher CEO Marc Casper, the PPD acquisition will allow the company to partner with drug companies from the earliest stages of laboratory research into new drugs through clinical trials and drug manufacturing
- In the short term, Casper said the transaction would help Thermo Fisher gain market share and accelerate growth. Longer term, the merger could help shorten the development time of new drugs by streamlining the process and reducing handoffs between vendors
- According to Johnathan Palmer a healthcare analyst for Bloomberg Intelligence, "PPD is one of the largest contract research organizations, with scale in clinical, preclinical and central lab end-markets. The marriage of PPD with Thermo's Patheon manufacturing unit would create a compelling end-to-end offering for biopharma customers, with compelling financial metrics"
- The transaction is expected to be immediately and significantly accretive to Thermo Fisher's adjusted EPS, adding \$1.40 in the first 12 months after close
- Thermo Fisher also expects to realize total synergies of approximately \$125 million by year three following close, consisting of approximately \$75 million of cost synergies and approximately \$50 million of adjusted operating income benefit from revenuerelated synergies

DELANCEY STREET PARTNERS, LIC




Historical Revenue Growth ⁽²⁾

(\$ in millions)



Historical Adjusted EBITDA Growth ⁽²⁾






(3) LTM as of 10/31/2011

Company press releases, investor presentations, and public filings
Public financial information is not available from 2012-2013


5



LTM EV / LTM EBITDA Multiple ^{(1) (2) (3)}



LTM EBITDA Margin % ^{(1) (2) (3)}




(1) Source(s): PitchBook, company press releases, investor presentations, and public filings

(2) Reflects median of the DSP CRO Companies Index

(3) Other DSP Outsourced Pharma Services Companies include: ICON, PRA Health, Medpace, IQVIA, Charles River Laboratories, Syneos Health, and LabCorp

FY 2020 Revenue Growth Rate % (1) (2) (3)





Transaction

Executive Commentary



"This is a very exciting announcement for our shareholders and will provide customers with an even better opportunity to bring meaningful innovation to the market faster and more efficiently. Thermo Fisher is a world-class company with a very similar culture and values and will provide a great foundation for our colleagues to continue to deliver for our customers and to develop their own skills and careers."

- Dave Simmons, Chairman & Chief Executive Officer, PPD

acquired by



"Pharma and Biotech is our largest and fastest growing end market, and our customers value us as a strategic partner and an industry leader. The acquisition of PPD is a natural extension for Thermo Fisher and will enable us to provide these customers with important clinical research services and partner with them in new and exciting ways as they move a scientific idea to an approved medicine quickly, reliably and cost effectively. Longer term, we plan to continue to invest in and connect the capabilities across the combined company to further help our customers accelerate innovation and drive productivity, while driving further value for our shareholders. Both companies have complementary mission-driven cultures, and I can't wait to welcome PPD's colleagues from around the world to Thermo Fisher once the transaction is completed."

– Marc N. Casper, Chairman, President, and Chief Executive Officer, Thermo Fisher Scientific

DELANCEY STREET PARTNERS RECENT HEALTHCARE TRANSACTION EXPERIENCE



CI CAPITAL PARTNERS

Advisor to Seller

Recapitalizations

M&A Advisory

Growth Capital

in a

Management Buyout

Advisor to Independent Committe Fairness Opinion

B. Andrew Schmucker

MEDNAX

Advisor to Seller

Managing Partner 484.533.6313 aschmucker@delanceyllc.com Patrick E. Dolan Managing Director 484.533.6311 pdolan@delanceyllc.com William J. Filip Managing Director 484.533.6312 wfilip@delanceyllc.com

METTLER TOLEDO

Advisor to Seller

Board Advisory

Strategic Evaluations

Steven D. Higgins Managing Director 484.533.6308 shiggins@delanceyllc.com

METTLER TOLEDO

Advisor to Seller